Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1)
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Rheumatology"
DOI: 10.1007/s10067-019-04863-0
Abstract: Introduction Although there is abundant evidence of vascular perturbation from studies of peripheral blood in systemic sclerosis (SSc), there are few data about the ability to use biomarkers of vascular injury and growth factors to… read more here.
Keywords: trial oral; trial; randomized controlled; oral treprostinil ... See more keywords
An Event-driven Trial for Oral Treprostinil. Progress but Not the Holy Grail
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Respiratory and Critical Care Medicine"
DOI: 10.1164/rccm.201912-2431ed
Abstract: Finally, this study suffers from underpowering, as it includes just 102 samples, less than half of which are the preinvasive AIS/MIA lesions of interest. Atypical alveolar hyperplasia, a presumed precursor of AIS, was not studied.… read more here.
Keywords: oral treprostinil; driven trial; treprostinil progress; trial oral ... See more keywords
Phase II trial of oral S-1 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard chemotherapies (CCOG-1105 study).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.841
Abstract: 841Background: The aim of this multicenter, single-arm phase II trial was to investigate the efficacy and safety of S-1 plus bevacizumab (BEV) as a salvage treatment for patients with metastatic co... read more here.
Keywords: trial oral; patients metastatic; oral plus; phase trial ... See more keywords